share_log

After Six Years Of Collaboration, Takeda Walks Away From Microbiome Drug Pact

After Six Years Of Collaboration, Takeda Walks Away From Microbiome Drug Pact

经过六年的合作，武田退出了微生物组药物协议
Benzinga Real-time News ·  2022/08/26 07:38
  • Finch Therapeutics Group Inc (NASDAQ:FNCH) will regain full development and commercial rights to FIN-524 (previously known as TAK-524) and FIN-525 from Takeda Pharmaceutical Company Ltd (NYSE:TAK). 
  • Following a review of its pipeline, Takeda will terminate its collaboration with Finch, effective November 17, 2022, resulting in the return to Finch of worldwide rights to develop and commercialize FIN-524, FIN-525, and any other microbiome product candidates for inflammatory bowel disease (IBD). 
  • Also Read: Takeda To Lead Finch-Partnered Microbiome IBD Drug.
  • "We are currently conducting a review of our portfolio and assessing the financial and strategic impact of the discontinuation of our collaboration with Takeda," said Mark Smith, CEO of Finch Therapeutics. 
  • Finch has received more than $44 million from Takeda during the collaboration, including an upfront payment of $10 million, $4 million in milestone payments, and more than $30 million in reimbursement of R&D expenses. 
  • Upon termination, Finch will receive a royalty-free license to all data and intellectual property generated during the collaboration.
  • FIN-524 and FIN-525 are investigational, orally administered targeted microbiome product candidates composed of bacterial strains selected for their potential immuno-modulatory properties.
  • Price Action: FNCH shares closed at $2.64, and TAK stock closed at $14.02 on Thursday.
  • 芬奇治疗集团公司(纳斯达克股票代码：FNCH)将从以下公司重新获得FIN-524(以前称为TAK-524)和FIN-525的全部开发和商业权武田药品株式会社(纽约证券交易所股票代码：Tak)。
  • 在对其流水线进行审查后，武田将从2022年11月17日起终止与芬奇的合作，导致芬奇重新获得开发和商业化FIN-524、FIN-525和任何其他用于炎症性肠病(IBD)的微生物组产品的全球权利。
  • 另请阅读： 武田将领导与Finch合作的微生物组IBD药物.
  • “我们目前正在对我们的投资组合进行审查，并评估我们终止与武田合作的财务和战略影响，”芬奇治疗公司首席执行官马克·史密斯说。
  • 芬奇在合作期间从武田收到了超过4400万美元，包括1000万美元的预付款，400万美元的里程碑付款，以及3000多万美元的研发费用报销。
  • 终止后，Finch将获得合作期间产生的所有数据和知识产权的免版税许可。
  • FIN-524和FIN-525是研究中的、口服给药的靶向微生物组产品，由可能具有免疫调节特性的细菌菌株组成。
  • 价格行动：FNCH股价周四收于2.64美元，TAK股价收于14.02美元。
声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发